Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $1.6 million.

  • Artiva Biotherapeutics' Share-based Compensation fell 14.47% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 19.84%. This contributed to the annual value of $7.0 million for FY2024, which is 1.04% down from last year.
  • Artiva Biotherapeutics' Share-based Compensation amounted to $1.6 million in Q3 2025, which was up 5.29% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Share-based Compensation ranged from a high of $2.2 million in Q4 2024 and a low of $1.4 million during Q3 2023.
  • In the last 3 years, Artiva Biotherapeutics' Share-based Compensation had a median value of $1.5 million in 2025 and averaged $1.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 56.90% in 2024, then dropped by 14.47% in 2025.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Share-based Compensation stood at $1.4 million in 2023, then soared by 56.90% to $2.2 million in 2024, then declined by 14.47% to $1.6 million in 2025.
  • Its Share-based Compensation stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and $2.1 million for Q1 2025.